Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 6Brain Neoplasms 4Oligodendroglioma 3Lymphoma, Follicular 3Gliosarcoma 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Optic Nerve Glioma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Sezary Syndrome 1Renal Insufficiency 1Recurrence 1Primary Myelofibrosis 1

Interventions

Cetuximab 6Cisplatin 4pembrolizumab 3Fluorouracil 3zalutumumab 2Paclitaxel 2Nivolumab 2Gefitinib 2temsirolimus 1sintilimab 1osimertinib 1cobimetinib 1Vorinostat 1Sorafenib 1Risk Factors 1Ribavirin 1Radiotherapy 1Proflavine 1Pemetrexed 1Jogging 1Imatinib Mesylate 1Docetaxel 1Dexamethasone 1Cyclophosphamide 1Cilengitide 1Carboplatin 1Calcium Dobesilate 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Squamous Cell × Cilengitide × Clear all
NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡